EUVIMEDSkopri EUVIMED
Crossref

Phytotherapeutic Potential of Cymbopogon citratus (Lemongrass) Extracts in Ameliorating Hyperglycemia: An In Vitro and In Vivo Assessment of Its Antidiabetic Efficacy

African Journal of Biomedical Research · 2024 · 27 (1)

DOI: 10.69980/f ↗

At a glance

Journal article in African Journal of Biomedical Research, 2024.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

As a result of the increasing prevalence of hyperglycaemia due to diabetes mellitus, plant derived adjuncts to treatment of diabetes have kept their interest alive due to their cost, tolerability and duration limitations. Cymbopogon citratus (DC.) Many herbs including stapf (lemongrass) are used as a therapeutic drink in Africa, Asia and Latin America for diabetes, but have not typically been critically assessed for their therapeutic value beyond mere documentation. The present review aims to compile, summarize, and analyze in vitro and in vivo studies related to the antihyperglycaemic effect of C. citratus, correlate this activity with specific phytochemical classes and evaluate its translatability. Secondary data were obtained from peer reviewed pharmacology, phytochemical, toxicological and clinical sources. The evidence is internally consistent on three points: the leaf extracts containing flavones have shown effect on down-regulated fasting glucose and glucose tolerance in chemically induced diabetic rodents; the essential oil responsible for most of the activities of carbohydrase inhibition is separated from the flavonic extracts; and the most internally consistent finding is the suppression of endoplasmic reticulum stress and up-regulation of Nrf2 in pancreatic tissue following application of the flavone glycoside extracts. Evidence on the magnitude of glycaemic effect is variable (ranging from 19.8% to 60.3% reductions) and α-glucosidase inhibition is not uniform for solvent systems and does not necessarily stimulate insulin secretion. Most importantly, no RCT study has looked at glycaemic endpoints in humans and the one available showed no change of serum glucose. C. citratus is thus considered a candidate that has good pharmacological potential but poor toxicological safety and is acclaimed for its antidiabetic properties solely on the basis of short-term studies carried out in rodents with extracts without characterization. Next, ways of preparing the animals have to be standardised, work needs to be done mechanistically in well-defined cellular models, and clinical trials must be sufficiently powered.

Cite

APA

(2024). Phytotherapeutic Potential of Cymbopogon citratus (Lemongrass) Extracts in Ameliorating Hyperglycemia: An In Vitro and In Vivo Assessment of Its Antidiabetic Efficacy. African Journal of Biomedical Research, 27(1). https://doi.org/10.69980/f

Vancouver

Phytotherapeutic Potential of Cymbopogon citratus (Lemongrass) Extracts in Ameliorating Hyperglycemia: An In Vitro and In Vivo Assessment of Its Antidiabetic Efficacy. African Journal of Biomedical Research. 2024;27(1). doi:10.69980/f

BibTeX
@article{euvimed2024,
  title = {Phytotherapeutic Potential of Cymbopogon citratus (Lemongrass) Extracts in Ameliorating Hyperglycemia: An In Vitro and In Vivo Assessment of Its Antidiabetic Efficacy},
  journal = {African Journal of Biomedical Research},
  year = {2024},
  volume = {27},
  number = {1},
  doi = {10.69980/f}
}
Start for free →